{"342081":{"#nid":"342081","#data":{"type":"news","title":"Treating Cancer: Researchers Develop and Improve Techniques for Attacking Cancer","body":[{"value":"\u003Cp\u003ECancer treatment typically involves surgery, radiation therapy, chemotherapy, hormone therapy or biological therapy. An oncologist may use one therapy or a combination of methods, depending on the type and location of the cancer, whether the disease has spread, the patient\u2019s age and general health, and other factors.\u003C\/p\u003E\u003Cp\u003EAt Georgia Tech, researchers are pursuing many different directions toward improving existing cancer treatment methods and developing new therapeutic techniques, including:\u003C\/p\u003E\u003Cul\u003E\u003Cli\u003EAttacking cancer stem cells;\u003C\/li\u003E\u003Cli\u003EImproving radiation therapy;\u003C\/li\u003E\u003Cli\u003EIncluding motion and biological information in planning treatment;\u003C\/li\u003E\u003Cli\u003EAssessing a tumor\u2019s ability to create new blood vessels;\u003C\/li\u003E\u003Cli\u003EDeveloping a new approach to targeted cancer therapy;\u003C\/li\u003E\u003Cli\u003EIncreasing responses to chemotherapy;\u003C\/li\u003E\u003Cli\u003EEnabling personalized drug delivery; and\u003C\/li\u003E\u003Cli\u003EAnalyzing gene expression data to predict response to drugs.\u003C\/li\u003E\u003C\/ul\u003E\u003Cp\u003EThis is the third in a series of three reports focusing on cancer research at Georgia Tech. The first highlighted efforts to\u0026nbsp;\u003Ca href=\u0022http:\/\/gtresearchnews.gatech.edu\/understanding-cancer-origins\/\u0022 target=\u0022_blank\u0022\u003Eunderstand how cancer arises\u003C\/a\u003E, and the second featured\u0026nbsp;\u003Ca href=\u0022http:\/\/gtresearchnews.gatech.edu\/diagnosing-cancer\/\u0022 target=\u0022_blank\u0022\u003Ecancer detection and diagnostic techniques\u003C\/a\u003E.\u003C\/p\u003E\u003Ch3\u003E\u003Cstrong\u003EATTACKING CANCER STEM CELLS\u003C\/strong\u003E\u003C\/h3\u003E\u003Cp\u003ERecent evidence suggests that certain cancers may persist or recur after treatment because a few cells \u2013 called cancer stem cells \u2013 survive existing therapy and then seed new tumors. These stem cells can be particularly resistant to chemotherapy and radiation.\u003C\/p\u003E\u003Cp\u003E\u201cIn the future, effective cancer therapy may require the detection and elimination of cancer stem cells in tumors,\u201d said\u0026nbsp;\u003Ca href=\u0022http:\/\/www.bme.gatech.edu\/facultystaff\/faculty_record.php?id=2\u0022 target=\u0022_blank\u0022\u003EGang Bao\u003C\/a\u003E, the Robert A. Milton Chair in Biomedical Engineering in the\u0026nbsp;\u003Ca href=\u0022http:\/\/www.bme.gatech.edu\/\u0022 target=\u0022_blank\u0022\u003EWallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University\u003C\/a\u003E. \u201cDeveloping a method to detect cancer stem cells is challenging because evidence suggests there is only one cancer stem cell for every 100,000 to 1 million cancer cells in tumor tissue, so the method must be very sensitive.\u201d\u003C\/p\u003E\u003Cp\u003EBao and postdoctoral fellow Won Jong Rhee recently developed a new method that effectively discriminates cancer stem cells from other cancer cells by locating protein markers on the surface of stem cells and stem cell-specific genes inside cancer stem cells. The work was published on April 2, 2009, in the journal\u0026nbsp;\u003Cem\u003E\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1186\/1472-6750-9-30\u0022 target=\u0022_blank\u0022\u003EBMC Biotechnology\u003C\/a\u003E\u003C\/em\u003E.\u003C\/p\u003E\u003Cp\u003EThe researchers located live stem cells by simultaneously detecting the presence of the stem cell surface protein marker SSEA-1 with dye-labeled antibodies and stem cell-specific mRNA \u2013 called Oct-4 \u2013 inside the stem cells using molecular beacons.\u003C\/p\u003E\u003Cp\u003E\u201cBy fluorescently imaging the level of Oct-4 mRNA in the cytoplasm of live stem cells with molecular beacons, we were able to increase the detection sensitivity and specificity,\u201d explained Bao, who is also a Georgia Tech College of Engineering Distinguished Professor.\u003C\/p\u003E\u003Cp\u003ESince initially developing this method for detecting and isolating stem cells, the research team has been improving the method\u2019s efficiency and specificity by targeting multiple mRNAs and cell surface markers using molecular beacons and antibodies.\u003C\/p\u003E\u003Cp\u003EAccording to Bao, the next stage for this research is to isolate cancer stem cells from human tumor tissue samples.\u003C\/p\u003E\u003Cp\u003E\u201cAfter we isolate the cancer stem cells, we still need to learn more about them, including the pathways or genes responsible for their development and whether they behave the same when isolated from different patients. Then we need to identify drug molecules that can kill them,\u201d he added.\u003C\/p\u003E\u003Cp\u003E\u003Cem\u003EFunding for this research is provided by the Emory-Georgia Tech National Cancer\u0026nbsp;Institute Center for Cancer Nanotechnology Excellence (CCNE). This work was funded by grant number U54CA119338 from the National Institutes of Health (NIH). The content is solely the responsibility of the principal investigator and does not necessarily represent the official\u0026nbsp;view of the NIH.\u003C\/em\u003E\u003C\/p\u003E\u003Ch3\u003E\u003Cstrong\u003EIMPROVING RADIATION THERAPY\u003C\/strong\u003E\u003C\/h3\u003E\u003Cp\u003EOne critical challenge in radiation therapy has always been how best to minimize damage\u0026nbsp;to normal tissue while delivering therapeutic doses to cancer cells. Intensity-modulated radiation therapy (IMRT) is an advanced type of radiation treatment that utilizes computer-controlled linear accelerators to deliver precise radiation doses to tumors while avoiding critical organs. Clinicians can use IMRT to treat difficult-to-reach tumors \u2013 such as tumors in the brain, head, neck, prostate, lung and liver \u2013 with new levels of accuracy.\u003C\/p\u003E\u003Cp\u003E\u201cConstructing an IMRT treatment plan that radiates the cancerous tumor without impacting adjacent normal structures is challenging,\u201d explained\u0026nbsp;\u003Ca href=\u0022http:\/\/www.isye.gatech.edu\/faculty-staff\/profile.php?entry=sa94\u0022 target=\u0022_blank\u0022\u003EShabbir Ahmed\u003C\/a\u003E, an associate professor in the\u0026nbsp;\u003Ca href=\u0022http:\/\/www.isye.gatech.edu\/\u0022 target=\u0022_blank\u0022\u003EStewart School of Industrial and Systems Engineering\u003C\/a\u003E\u0026nbsp;at Georgia Tech. \u201cBecause of the many possible beam geometries and the range of intensities, there are an infinite number of treatment plans and many metrics to assess their quality.\u201d\u003C\/p\u003E\u003Cp\u003ETo develop better treatment plans faster, Ahmed began working with School of Industrial and Systems Engineering professor\u0026nbsp;\u003Ca href=\u0022http:\/\/www.isye.gatech.edu\/faculty-staff\/profile.php?entry=ms79\u0022 target=\u0022_blank\u0022\u003EMartin Savelsbergh\u003C\/a\u003E\u0026nbsp;and graduate student Halil Ozan Gozbasi, as well as collaborators Ian Crocker, Timothy Fox and Eduard Schreibmann from the Emory University School of Medicine\u2019s Department of Radiation Oncology. Funding for this research\u0026nbsp;was provided by Emory University.\u003C\/p\u003E\u003Cp\u003EThe Georgia Tech researchers built on an existing model and developed a fully automated program that simultaneously generates several high-quality treatment plans satisfying the clinician-provided requirements. The optimization program uses three-dimensional computed tomography images of the patient and information about (1) the type, location and size of the tumor; (2) maximum allowable doses to non-cancerous organs; and (3) the patient\u2019s health.\u003C\/p\u003E\u003Cp\u003E\u201cPrevious models would produce one treatment plan in an hour and then if it was not exactly what the clinician wanted, someone would have to change the requirements and rerun the program to create a new treatment plan,\u201d explained Ahmed. \u201cOur program produces several optimized solutions in a fraction of the time.\u201d\u003C\/p\u003E\u003Cp\u003EThe technology, which has been tested successfully on real brain, head\/neck and prostate cancer cases, produces clinically acceptable treatment plans in less than 15 minutes.\u003C\/p\u003E\u003Ch3\u003E\u003Cstrong\u003EINCLUDING MOTION AND BIOLOGICAL INFORMATION IN TREATMENT PLANNING\u003C\/strong\u003E\u003C\/h3\u003E\u003Cp\u003EIntensity-modulated radiation therapy (IMRT) treatment planning is challenging because some organs, such as the prostate, move due to normal daily volume changes in the bladder and rectum. In addition, a tumor can change shape during radiation treatment, which typically lasts five days a week for five to 10 weeks.\u003C\/p\u003E\u003Cp\u003E\u003Ca href=\u0022http:\/\/www.isye.gatech.edu\/faculty-staff\/profile.php?entry=el44\u0022 target=\u0022_blank\u0022\u003EEva Lee\u003C\/a\u003E, an associate professor in the\u0026nbsp;\u003Ca href=\u0022http:\/\/www.isye.gatech.edu\/\u0022 target=\u0022_blank\u0022\u003EStewart School of Industrial and Systems Engineering\u003C\/a\u003E\u0026nbsp;at Georgia Tech, and Joseph Deasy, a professor and director of the Division of Bioinformatics and Outcomes Research in the Department of Radiation Oncology at Washington University in St. Louis,are addressing motion issues with liver and lung cancer patients.\u003C\/p\u003E\u003Cp\u003EBy collecting computed tomography images over time, the researchers can track every spatial point of interest in the tumor and surrounding area during each phase of the breathing cycle. This allows them to develop treatment plans that account for breathing, motion and shape changes throughout the treatment regimen.\u003C\/p\u003E\u003Cp\u003E\u201cAccounting for motion in the image-guided treatment planning dramatically improves under-dosing the tumor tissue and even reduces the dose to normal tissue and critical organs,\u201d noted Eva Lee, who is also director of the Center for Operations Research in Medicine and HealthCare at Georgia Tech.\u003C\/p\u003E\u003Cp\u003EIn lung cancer cases, that means reducing the average dose of radiation to the normal lung tissue, heart and esophagus. For liver cancer, the researchers have reduced the radiation delivered to normal liver and non-liver tissues.\u003C\/p\u003E\u003Cp\u003EIn another project, Lee and Marco Zaider, an attending physicist and head of brachytherapy physics in medical physics at Memorial Sloan-Kettering Cancer Center in New York, are incorporating biological information into treatment planning for prostate cancer IMRT and brachytherapy \u2013 the placement of radioactive \u201cseeds\u201d inside a tumor.\u003C\/p\u003E\u003Cp\u003EUsing magnetic resonance spectroscopy, the researchers identified regions of the prostate that had denser populations of tumor cells. These areas could then be targeted with an escalated radiation dose, while maintaining a minimal dose to critical and normal tissues.\u003C\/p\u003E\u003Cp\u003E\u201cOne of our main concerns is avoiding normal tissue toxicity, so by targeting only the \u2018bad\u2019 pockets of tumor cells, we hope to improve the outcome,\u201d said Zaider. \u201cBiological optimization attempts to target tissue that is potentially responsible for metastatic spread.\u201d\u003C\/p\u003E\u003Cp\u003ELee\u2019s research has been supported by the\u0026nbsp;\u003Ca href=\u0022http:\/\/www.nsf.gov\/\u0022 target=\u0022_blank\u0022\u003ENational Science Foundation\u003C\/a\u003E\u0026nbsp;(NSF), the\u0026nbsp;\u003Ca href=\u0022http:\/\/www.nih.gov\/\u0022 target=\u0022_blank\u0022\u003ENational Institutes of Health\u003C\/a\u003E\u0026nbsp;(NIH) and the Whitaker Foundation.\u003C\/p\u003E\u003Cp\u003E\u003Cem\u003EThis project was partially supported by Award No. 0800057 from the NSF and Award No. 5UL1RR025008-02 from the NIH. The content is solely the responsibility of the principal investigator and does not necessarily represent the official views of the NSF or NIH.\u003C\/em\u003E\u003C\/p\u003E\u003Ch3\u003E\u003Cstrong\u003EASSESSING A TUMOR\u2019S ABILITY TO CREATE NEW BLOOD VESSELS\u003C\/strong\u003E\u003C\/h3\u003E\u003Cp\u003ECancer manifests itself in different ways \u2013 some cancers proceed slowly, while others spread aggressively. These differences have led clinicians to believe that personalized cancer therapies might be the best solution for treating the disease.\u003C\/p\u003E\u003Cp\u003ENow, new research, published in the June 2009 issue of the journal\u0026nbsp;\u003Cem\u003E\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1371\/journal.pone.0005843\u0022 target=\u0022_blank\u0022\u003EPLoS ONE\u003C\/a\u003E\u003C\/em\u003E, is providing insight into the aggressiveness of tumors. This information could facilitate development of a personalized treatment regimen.\u003C\/p\u003E\u003Cp\u003EBecause aggressive tumors create more new blood vessels to sustain their growth, researchers designed long-circulating nanoprobes that were 100 nanometers in diameter and contained\u0026nbsp;a contrast agent that could only seep into tumors from blood vessels that were growing and therefore leaky.\u003C\/p\u003E\u003Cp\u003E\u201cWe exploited the fact that the nanoprobes are too big to leak out of normal blood vessels, but they can leak out of newly forming tumor vessels because these immature vessels have bigger holes in them,\u201d explained lead author\u0026nbsp;\u003Ca href=\u0022http:\/\/www.bme.gatech.edu\/facultystaff\/faculty_record.php?id=59\u0022 target=\u0022_blank\u0022\u003ERavi Bellamkonda\u003C\/a\u003E, a professor in the Wallace H. Coulter\u0026nbsp;\u003Ca href=\u0022http:\/\/www.bme.gatech.edu\/\u0022 target=\u0022_blank\u0022\u003EDepartment of Biomedical Engineering\u003C\/a\u003E\u0026nbsp;at Georgia Tech and Emory University.\u003C\/p\u003E\u003Cp\u003EThe study showed that the degree of \u201cleakiness\u201d of tumor blood vessels to the nanoprobe correlates to its expression of vascular endothelial growth factor (VEGF), a protein that stimulates the growth of new blood vessels in tumors.\u003C\/p\u003E\u003Cp\u003E\u201cClinical studies have shown that VEGF expression varies among tumors, with higher levels of VEGF expression correlating with unfavorable prognosis, but scientists haven\u2019t been able to non-invasively determine VEGF expression levels in individual tumors until now,\u201d said Bellamkonda, who is also a\u0026nbsp;\u003Ca href=\u0022http:\/\/www.georgiacancer.org\/\u0022 target=\u0022_blank\u0022\u003EGeorgia Cancer Coalition\u003C\/a\u003E\u0026nbsp;Distinguished Scholar.\u003C\/p\u003E\u003Cp\u003EAfter injecting the contrast-containing nanoprobes into rats with six-day-old breast cancer tumors, the research team visualized the levels of nanoprobe accumulation in the tumor using digital mammography. The results showed increased \u201cleakiness,\u201d nanoprobe accumulation and tumor growth rates in tumors with higher levels of VEGF. Similar-size tumors showed various degrees of angiogenesis and blood vessel permeability, which caused them to behave differently, emphasizing the inherent variability in tumors and the need for a personalized approach to each tumor.\u003C\/p\u003E\u003Cp\u003E\u201cIn the future, instead of just measuring the size of a tumor, clinicians can quantify the leakiness of tumor blood vessels to determine the extent of angiogenesis in each tumor and decide which patients should undergo anti-angiogenic therapy or other aggressive treatment regimens,\u201d added Bellamkonda.\u003C\/p\u003E\u003Cp\u003ECollaborators on this research include Efstathios Karathanasis, formerly a Coulter Department postdoctoral fellow and currently an assistant professor in the Department of Biomedical\u0026nbsp;Engineering at Case Western Reserve University; Carl D\u2019Orsi and Ioannis Sechopoulos of the Department of Radiology and Winship Cancer Institute at the Emory University School of Medicine; and Ananth Annapragada, an associate professor of health information sciences at the University of Texas, Houston.\u003C\/p\u003E\u003Cp\u003E\u003Cem\u003EThis project is supported by the National Science Foundation (NSF) (Award Nos. 0401627 and ERC-EEC-9731643), the Nora Reed Foundation, the Wallace H. Coulter Foundation and the Georgia Cancer Coalition. The content is solely the responsibility of the principal investigator and does not necessarily represent the official view of the NSF.\u003C\/em\u003E\u003C\/p\u003E\u003Ch3\u003E\u003Cstrong\u003EDEVELOPING A NEW APPROACH TO TARGETED CANCER THERAPY\u003C\/strong\u003E\u003C\/h3\u003E\u003Cp\u003EA new therapeutic strategy for cancer treatment is to inhibit enzymes called histone deacetylases, which play an important role in the regulation of gene expression. Vorinostat (SAHA) \u2013 a histone deacetylase inhibitor \u2013 was approved by the U.S. Food and Drug Administration in 2006 to treat an immune system cancer called cutaneous T-cell lymphoma.\u003C\/p\u003E\u003Cp\u003EWhile these inhibitors are clinically valuable, they typically inhibit many of the 18 different histone deacetylase subtypes, a process that can be harmful to essential cell functions throughout the body.\u003C\/p\u003E\u003Cp\u003E\u201cOur goal is to create inhibitors for these enzymes that target specific cancerous organs so that we can exploit their anti-cancer activity in the cancerous tissue areas only and not negatively\u003C\/p\u003E\u003Cp\u003Eaffect other areas of the body,\u201d said\u0026nbsp;\u003Ca href=\u0022http:\/\/www.chemistry.gatech.edu\/faculty\/Oyelere\/\u0022 target=\u0022_blank\u0022\u003EAdegboyega \u201cYomi\u201d K. Oyelere\u003C\/a\u003E, who holds the Blanchard Assistant Professorship in the Georgia Tech\u0026nbsp;\u003Ca href=\u0022http:\/\/www.chemistry.gatech.edu\/\u0022 target=\u0022_blank\u0022\u003ESchool of Chemistry and Biochemistry\u003C\/a\u003E.\u003C\/p\u003E\u003Cp\u003EIn the January 22, 2009, issue of the\u0026nbsp;\u003Cem\u003E\u003Ca href=\u0022http:\/\/dx.doi.org\/10.1021\/jm801128g\u0022 target=\u0022_blank\u0022\u003EJournal of Medicinal Chemistry\u003C\/a\u003E\u003C\/em\u003E, Oyelere and Georgia Tech biology assistant professor\u0026nbsp;\u003Ca href=\u0022http:\/\/www.biology.gatech.edu\/faculty\/yuhong-fan\/\u0022 target=\u0022_blank\u0022\u003EYuhong Fan\u003C\/a\u003E\u0026nbsp;described a new class of potent non-peptide histone deacetylase inhibitors that can be selectively accumulated in the lungs.\u003C\/p\u003E\u003Cp\u003ETo create them, the researchers modified the amine sugar portion of common antibiotics such as azithromycin and clarithromycin with a histone deacetylase inhibiting structure. Experiments have shown that the new compounds are more potent than SAHA and are lung-specific. As a result of these preliminary findings, Oyelere was recently awarded a five-year, $1.5 million grant from the\u0026nbsp;\u003Ca href=\u0022http:\/\/www.nih.gov\/\u0022 target=\u0022_blank\u0022\u003ENational Institutes of Health\u003C\/a\u003E\u0026nbsp;to continue this lung cancer research.\u003C\/p\u003E\u003Cp\u003EOyelere is also designing histone deacetylase inhibitors that can be taken up by the hormones expressed on the surface of hormone-positive breast cancer cells to stop the cells from dividing.\u003C\/p\u003E\u003Cp\u003EFor this project, he is working with\u0026nbsp;\u003Ca href=\u0022http:\/\/www.chemistry.gatech.edu\/faculty\/Doyle\/\u0022 target=\u0022_blank\u0022\u003EDonald Doyle\u003C\/a\u003E, an associate professor in the Georgia Tech School of Chemistry and Biochemistry.\u003C\/p\u003E\u003Cp\u003E\u201cA majority of hormone-positive breast cancers develop resistance to anti-cancer hormone drugs, so if we can exploit the ability of our compounds to be accepted by hormone-positive breast cancers, whether they\u2019re resistant or not, this could lead to the identification of new, broad anti-cancer agents for targeted cancer therapy,\u201d explained Oyelere.\u003C\/p\u003E\u003Cp\u003ENext up on Oyelere\u2019s list of cancers to tackle with this approach is prostate cancer.\u003C\/p\u003E\u003Cp\u003E\u003Cem\u003EThis work is funded by grant number R01CA131217 from the National Institutes of Health (NIH). The content is solely the responsibility of the principal investigator and does not necessarily represent the official view of the NIH.\u003C\/em\u003E\u003C\/p\u003E\u003Ch3\u003E\u003Cstrong\u003EINCREASING RESPONSES TO CHEMOTHERAPY\u003C\/strong\u003E\u003C\/h3\u003E\u003Cp\u003E\u003Ca href=\u0022http:\/\/www.chbe.gatech.edu\/fac_staff\/faculty\/taite.php\u0022 target=\u0022_blank\u0022\u003ELakeshia Taite\u003C\/a\u003E\u0026nbsp;is investigating ways to smuggle powerful chemotherapeutic drugs and chemical compounds into tumor cells, thus increasing the drugs\u2019 cancer-killing activities and reducing their toxic side effects on healthy cells.\u003C\/p\u003E\u003Cp\u003EAs an assistant professor in the Georgia Tech\u0026nbsp;\u003Ca href=\u0022http:\/\/www.chbe.gatech.edu\/\u0022 target=\u0022_blank\u0022\u003ESchool of Chemical and Biomolecular Engineering\u003C\/a\u003E, Taite is developing cancer drug delivery vehicles composed of a gold nanoshell core with dendrimers attached to the surface. Dendrimers are polymers that exhibit a tree-like structure with many branches and cavities where chemotherapy drugs can be encapsulated.\u003C\/p\u003E\u003Cp\u003EThe dendrimers are synthesized with targeting molecules on their surfaces that can seek out and bind to cancer cells. Introduced into the body, they bind to cancer cells, and when near-infrared light shines on the body, the gold nanoshell heats up. That heat leads the dendrimers to shrink, the drug to be released, and the tumor cells are exposed to both the heat and drug therapies.\u003C\/p\u003E\u003Cp\u003E\u201cIn some cases, ablation takes place at temperatures that can be uncomfortable to the patient, so we are trying to develop dendrimers that require lower transition temperatures to release the drug,\u201d said Taite. \u201cWe believe that even if the lower temperature does not kill all of the cancer cells, it will still damage them enough that they will become extremely vulnerable to the drug, ultimately still leading to cell death.\u201d\u003C\/p\u003E\u003Cp\u003EAmanda Lowery, a research fellow in radiation oncology at Vanderbilt University, is collaborating with Taite on this research.\u003C\/p\u003E\u003Cp\u003ETaite is also designing another delivery vehicle to carry and release nitric oxide for the treatment of aggressive brain tumors. She is focusing on nitric oxide because it has the ability to cross the blood-brain barrier and help other molecules cross both the blood-brain barrier and the blood-tumor barrier.\u003C\/p\u003E\u003Cp\u003E\u201cNitric oxide has been shown to increase the sensitivity of certain tumors to chemotherapeutics and radiation, so we are working to form materials that can be attached to imaging particles and a chemotherapeutic that can be targeted to specific tumors. That would significantly enhance current tumor treatment approaches,\u201d explained Taite.\u003C\/p\u003E\u003Cp\u003EThe targeted nitric oxide delivery system will be used to study the efficacy of using nitric oxide to sensitize brain tumors to treatment and improve patient prognosis.\u003C\/p\u003E\u003Cp\u003E\u201cMy ultimate goal in designing all of these drug delivery systems is to improve patient quality of life and reduce cancer recurrence,\u201d added Taite.\u003C\/p\u003E\u003Ch3\u003E\u003Cstrong\u003EENABLING PERSONALIZED DRUG DELIVERY\u003C\/strong\u003E\u003C\/h3\u003E\u003Cp\u003EThe search is on for drug delivery systems that allow treatment to be tailored to an individual patient and a particular tumor. Researchers at Georgia Tech are contributing to the pursuit by developing ways to program the assembly and disassembly of multi-particle drug delivery vehicles.\u003C\/p\u003E\u003Cp\u003E\u201cCancer is a complicated disease, and we wanted to find a way that we could simultaneously deliver many different particles to the tumor site as a package and, upon arrival, break open the packages so that the individual particles could then carry out their particular functions,\u201d said\u0026nbsp;\u003Ca href=\u0022http:\/\/www.mse.gatech.edu\/FacultyStaff\/MSE_Faculty_researchbios\/Milam\/milam.html\u0022 target=\u0022_blank\u0022\u003EValeria Milam\u003C\/a\u003E, an assistant professor in the Georgia Tech\u0026nbsp;\u003Ca href=\u0022http:\/\/www.mse.gatech.edu\/\u0022 target=\u0022_blank\u0022\u003ESchool of Materials Science and Engineering\u003C\/a\u003E.\u003C\/p\u003E\u003Cp\u003EIndividuals benefit from this type of personalized treatment through the increase in the drug\u2019s cancer-killing power and the reduction of its toxic side effects. Milam and her students are using short nucleic acid polymers called oligonucleotides to connect the particle surfaces for simultaneous delivery of different therapeutic and diagnostic agents to the tumor site.\u003C\/p\u003E\u003Cp\u003E\u201cTo assemble the pieces, we are using short oligonucleotides as the glue because they have a weak, yet sufficient affinity for their partner strand,\u201d explained Milam, who is also a\u0026nbsp;\u003Ca href=\u0022http:\/\/www.georgiacancer.org\/\u0022 target=\u0022_blank\u0022\u003EGeorgia Cancer Coalition\u003C\/a\u003EDistinguished Cancer Scholar. \u201cThis allows us to direct particles A and B to attach to particle C through oligonucleotide linkages, while keeping particles A and B unconnected to one another.\u201d\u003C\/p\u003E\u003Cp\u003EThen, to disassemble the particle package, a competitive oligonucleotide \u2013 one with a stronger affinity as a partner strand \u2013 is introduced into the system. These competitive strands displace the original partner strands, allowing the package to break open. Milam and her team are further improving the drug delivery vehicle so that it can be initially camouflaged to avoid any host response that would clear it out of the body before arriving at the tumor site.\u003C\/p\u003E\u003Cp\u003E\u201cOur ongoing work involves initially masking the presence of the therapeutic carriers by applying a stealth coating to the vehicle surface,\u201d noted Milam. \u201cThen, after the desired circulation time, the coating will be shed to reveal cancer-targeting ligands.\u201d\u003C\/p\u003E\u003Cp\u003EWhile Milam\u2019s experiments are still at the laboratory stage, her ultimate goal is to develop materials that can be used in the clinical setting to treat cancer. Former Georgia Tech students Christopher Tison and Sonya Parpart, and current graduate students James Hardin and Bryan Baker, also worked on this research. This work is currently supported by the Georgia Cancer Coalition, a National Science Foundation CAREER award, and the U.S. Army. It was previously supported by the Emory-Georgia Tech National Cancer Institute Center for Cancer Nanotechnology Excellence (CCNE).\u003C\/p\u003E\u003Cp\u003E\u003Cem\u003EThis material is based upon work supported by the U.S. Army (Award No. W911NF-09-1-0479), National Institutes of Health (NIH) (Award No. U54CA119338) and National Science Foundation (NSF) (Award No. DMR-0847436). Any opinions, finding, conclusions or recommendations expressed are those of the principal investigator and do not necessarily reflect the views of the U.S. Army, NIH or NSF.\u003C\/em\u003E\u003C\/p\u003E\u003Ch3\u003E\u003Cstrong\u003EANALYZING GENE EXPRESSION DATA TO PREDICT DRUG RESPONSE\u003C\/strong\u003E\u003C\/h3\u003E\u003Cp\u003EThe major clinical goals in applying gene expression profiling to cancer are to develop predictors of drug response that will guide more individualized therapies.\u003C\/p\u003E\u003Cp\u003E\u003Ca href=\u0022http:\/\/www.isye.gatech.edu\/faculty-staff\/profile.php?entry=my46\u0022 target=\u0022_blank\u0022\u003EMing Yuan\u003C\/a\u003E, an associate professor in the Stewart\u0026nbsp;\u003Ca href=\u0022http:\/\/www.isye.gatech.edu\/\u0022 target=\u0022_blank\u0022\u003ESchool of Industrial and Systems Engineering\u003C\/a\u003E\u0026nbsp;at Georgia Tech, is using computational and mathematical approaches to analyze how gene expression evolves over time in individuals with breast cancer and whether these patterns can predict treatment outcome. Specifically, Yuan is studying how gene expression evolves during\u0026nbsp;the menstrual cycle and whether there is any association between these patterns and cancer relapse.\u003C\/p\u003E\u003Cp\u003E\u201cOur goal is to weed out the genes that just change expression level due to a woman\u2019s menstrual cycle and not because of tumor progression or treatment,\u201d explained Yuan, who is also a\u0026nbsp;\u003Ca href=\u0022http:\/\/www.georgiacancer.org\/\u0022 target=\u0022_blank\u0022\u003EGeorgia Cancer Coalition\u003C\/a\u003EDistinguished Cancer Scholar. \u201cWe want to know which genes are abnormally expressed over time and behave differently than the majority of genes because that would make them likely drug targets.\u201d\u003C\/p\u003E\u003Cp\u003EBetter predictors of relapse risk could help cancer patients make better treatment decisions in consultation with their physicians. Yuan is working with William Hrushesky of the University of South Carolina and the Dorn Veterans Affairs Medical Center on this research.\u003C\/p\u003E\u003Cp\u003EIn another project, Yuan is collaborating with two University of Wisconsin professors, Alan Attie and Christina Kendziorski, to conduct expression quantitative trait loci (eQTL) studies. This analysis allows the researchers to identify genomic hot spots that regulate gene transcription and expression on a genome-wide scale.\u003C\/p\u003E\u003Cp\u003E\u201cWe want to determine which regions of the genome are most predictive of expression variations, but it\u2019s challenging because there are a vast range of possible regulatory loci and many of them are correlated, making it hard to differentiate which is actually responsible for a given effect,\u201d said Yuan.\u003C\/p\u003E\u003Cp\u003EYuan\u2019s analysis will determine the hot spots as well as how those genes are connected to each other, but ultimately, the proposed genes will need to be studied further by biologists.\u003C\/p\u003E\u003Cp\u003EYuan\u2019s research is supported by the National Science Foundation and the Georgia Cancer Coalition.\u003C\/p\u003E\u003Cp\u003E\u003Cem\u003EThis work was partly funded by grant number DMS-0846234 from the National Science Foundation (NSF). The content is solely the responsibility of the principal investigator and does not necessarily represent the official view of the NSF.\u003C\/em\u003E\u003C\/p\u003E\u003Cem\u003E\u003Cbr \/\u003E\u003C\/em\u003E\u0026nbsp;","summary":null,"format":"limited_html"}],"field_subtitle":"","field_summary":"","field_summary_sentence":[{"value":"t Georgia Tech, researchers are pursuing many different directions toward improving existing cancer treatment methods and developing new therapeutic techniques."}],"uid":"28152","created_gmt":"2014-11-05 17:37:04","changed_gmt":"2016-10-08 03:17:26","author":"Claire Labanz","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2010-04-07T00:00:00-04:00","iso_date":"2010-04-07T00:00:00-04:00","tz":"America\/New_York"},"extras":[],"hg_media":{"342001":{"id":"342001","type":"image","title":"Research Horizons - Treating Cancer - Gang Bao","body":null,"created":"1449245616","gmt_created":"2015-12-04 16:13:36","changed":"1475895060","gmt_changed":"2016-10-08 02:51:00","alt":"Research Horizons - Treating Cancer - Gang Bao","file":{"fid":"200785","name":"treating_cancer_image_1.jpg","image_path":"\/sites\/default\/files\/images\/treating_cancer_image_1_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/treating_cancer_image_1_0.jpg","mime":"image\/jpeg","size":1702516,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/treating_cancer_image_1_0.jpg?itok=3XdHkHuh"}},"342011":{"id":"342011","type":"image","title":"Research Horizons - Treating Cancer - Timothy Fox, Shabbir Ahmed, Halil Ozan Gozbasi and Eduard Schreibmann","body":null,"created":"1449245616","gmt_created":"2015-12-04 16:13:36","changed":"1475895060","gmt_changed":"2016-10-08 02:51:00","alt":"Research Horizons - Treating Cancer - Timothy Fox, Shabbir Ahmed, Halil Ozan Gozbasi and Eduard Schreibmann","file":{"fid":"200786","name":"treating_cancer_image_2.jpg","image_path":"\/sites\/default\/files\/images\/treating_cancer_image_2_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/treating_cancer_image_2_0.jpg","mime":"image\/jpeg","size":1948302,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/treating_cancer_image_2_0.jpg?itok=03Jec-Kx"}},"342021":{"id":"342021","type":"image","title":"research Horizons - Treating Cancer - four-dimensional IMRT treatment plan","body":null,"created":"1449245616","gmt_created":"2015-12-04 16:13:36","changed":"1475895060","gmt_changed":"2016-10-08 02:51:00","alt":"research Horizons - Treating Cancer - four-dimensional IMRT treatment plan","file":{"fid":"200787","name":"treating_cancer_image_3.jpg","image_path":"\/sites\/default\/files\/images\/treating_cancer_image_3_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/treating_cancer_image_3_0.jpg","mime":"image\/jpeg","size":48980,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/treating_cancer_image_3_0.jpg?itok=25dsaEnS"}},"342031":{"id":"342031","type":"image","title":"research Horizons - Treating Cancer - quantify the proteins responsible for new blood vessel","body":null,"created":"1449245616","gmt_created":"2015-12-04 16:13:36","changed":"1475895060","gmt_changed":"2016-10-08 02:51:00","alt":"research Horizons - Treating Cancer - quantify the proteins responsible for new blood vessel","file":{"fid":"200788","name":"treating_cancer_image_4.jpg","image_path":"\/sites\/default\/files\/images\/treating_cancer_image_4_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/treating_cancer_image_4_0.jpg","mime":"image\/jpeg","size":1559957,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/treating_cancer_image_4_0.jpg?itok=WRXO7SwC"}},"342041":{"id":"342041","type":"image","title":"research Horizons - Treating Cancer - compound design principles","body":null,"created":"1449245616","gmt_created":"2015-12-04 16:13:36","changed":"1475895062","gmt_changed":"2016-10-08 02:51:02","alt":"research Horizons - Treating Cancer - compound design principles","file":{"fid":"200789","name":"treating_cancer_image_5.jpg","image_path":"\/sites\/default\/files\/images\/treating_cancer_image_5_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/treating_cancer_image_5_0.jpg","mime":"image\/jpeg","size":1820406,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/treating_cancer_image_5_0.jpg?itok=FEep-9Jv"}},"342051":{"id":"342051","type":"image","title":"research Horizons - Treating Cancer - cmuggle powerful chemotherapeutic drugs and chemical compounds into tumor cells","body":null,"created":"1449245616","gmt_created":"2015-12-04 16:13:36","changed":"1475895062","gmt_changed":"2016-10-08 02:51:02","alt":"research Horizons - Treating Cancer - cmuggle powerful chemotherapeutic drugs and chemical compounds into tumor cells","file":{"fid":"200790","name":"treating_cancer_image_6.jpg","image_path":"\/sites\/default\/files\/images\/treating_cancer_image_6_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/treating_cancer_image_6_0.jpg","mime":"image\/jpeg","size":1570197,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/treating_cancer_image_6_0.jpg?itok=G8sZ1Si3"}},"342061":{"id":"342061","type":"image","title":"research Horizons - Treating Cancer - multi-particle drug delivery vehicles","body":null,"created":"1449245616","gmt_created":"2015-12-04 16:13:36","changed":"1475895062","gmt_changed":"2016-10-08 02:51:02","alt":"research Horizons - Treating Cancer - multi-particle drug delivery vehicles","file":{"fid":"200791","name":"treating_cancer_image_7.jpg","image_path":"\/sites\/default\/files\/images\/treating_cancer_image_7_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/treating_cancer_image_7_0.jpg","mime":"image\/jpeg","size":1820121,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/treating_cancer_image_7_0.jpg?itok=1aNZhWEv"}},"342071":{"id":"342071","type":"image","title":"research Horizons - Treating Cancer - Ming Yuan,","body":null,"created":"1449245616","gmt_created":"2015-12-04 16:13:36","changed":"1475895062","gmt_changed":"2016-10-08 02:51:02","alt":"research Horizons - Treating Cancer - Ming Yuan,","file":{"fid":"200792","name":"treating_cancer_image_8.jpg","image_path":"\/sites\/default\/files\/images\/treating_cancer_image_8_0.jpg","image_full_path":"http:\/\/www.tlwarc.hg.gatech.edu\/\/sites\/default\/files\/images\/treating_cancer_image_8_0.jpg","mime":"image\/jpeg","size":983447,"path_740":"http:\/\/www.tlwarc.hg.gatech.edu\/sites\/default\/files\/styles\/740xx_scale\/public\/images\/treating_cancer_image_8_0.jpg?itok=oE7qGDCN"}}},"media_ids":["342001","342011","342021","342031","342041","342051","342061","342071"],"groups":[{"id":"1188","name":"Research Horizons"}],"categories":[{"id":"42941","name":"Art Research"}],"keywords":[{"id":"108281","name":"Winter 2010 Issue"}],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003E\u003Cstrong\u003EResearch News\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EGeorgia Institute of Technology\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003E177 North Avenue\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EAtlanta, Georgia 30332-0181\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003E\u0026nbsp;\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EMedia Relations Contacts:\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003E\u0026nbsp;\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EJohn Toon\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E404-894-6986\u003C\/p\u003E\u003Cp\u003E\u003Ca href=\u0022mailto:jtoon@gatech.edu\u0022\u003Ejtoon@gatech.edu\u003C\/a\u003E\u003C\/p\u003E\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\u003Cp\u003E\u003Cstrong\u003EBrett Israel\u003C\/strong\u003E\u003C\/p\u003E\u003Cp\u003E404-385-1933\u003C\/p\u003E\u003Cp\u003E\u003Ca href=\u0022mailto:brett.israel@comm.gatech.edu\u0022\u003Ebrett.israel@comm.gatech.edu\u003C\/a\u003E\u003C\/p\u003E\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E","format":"limited_html"}],"email":[],"slides":[],"orientation":[],"userdata":""}}}